Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 4 de 4
1.
Clin Infect Dis ; 2024 Apr 03.
Article En | MEDLINE | ID: mdl-38568992

BACKGROUND: In high-resource settings the survival of immunocompromised (IC) children has increased and immunosuppressive therapies are increasingly being used. This study aimed to determine the clinical characteristics, performance of diagnostic tools and outcome of IC children with TB in Europe. METHODS: Multicentre, matched case-control study within the Paediatric Tuberculosis Network European Trials Group (ptbnet), capturing TB cases <18 years diagnosed 2000-2020. RESULTS: 417 TB cases were included, comprising 139 children with IC (HIV, inborn errors of immunity, drug-induced immunosuppression and other immunocompromising conditions) and 278 non-IC children as controls. Non-respiratory TB was more frequent among cases than controls (32.4% vs. 21.2%; p = 0.013). IC patients had an increased likelihood of presenting with severe disease (57.6% vs. 38.5%; p < 0.001; OR [95% CI]: 2.073 [1.37-3.13]). Children with IC had higher rates of false-negative tuberculin skin test (31.9% vs. 6.0%; p < 0.001) and QuantiFERON-TB Gold assay (30.0% vs. 7.3%; p < 0.001) results at diagnosis. Overall, the microbiological confirmation rate was similar in IC and non-IC cases (58.3% vs. 49.3%; p = 0.083). Although the mortality in IC children was <1%, the rate of long-term sequelae was significantly higher than in non-IC cases (14.8% vs. 6.1%; p = 0.004). CONCLUSIONS: IC children with TB disease in Europe have increased rates of non-respiratory TB, severe disease, and long-term sequelae. Immune-based TB tests have poor sensitivity in those children. Future research should focus on developing improved immunological TB tests that perform better in IC patients, and determining the reasons for the increased risk of long-term sequelae, with the aim to design preventive management strategies.

2.
Clin Med (Lond) ; 23(2): 164-169, 2023 03.
Article En | MEDLINE | ID: mdl-36958840

We describe an active and latent tuberculosis (TB) screening programme undertaken in Manchester, UK in response to the arrival of a cohort of refugees from Afghanistan. In total, 217 adults and 347 children were offered screening, which involved a symptom questionnaire, Mantoux test or interferon gamma release assay, blood-borne virus screening and a chest X-ray in participants over the age of 11. We found a latent TB infection (LTBI) rate of 15% in adults and 1.5% in children, which is lower than global LTBI estimates. One case of active TB was detected. Screening was undertaken in the hotels where participants were temporarily housed, leading to high participant engagement levels. Attendance rates were almost doubled compared with a previous hospital-based screening programme. Hotel-based screening for TB presented several challenges, including transfer of information and results to secondary care. Understanding these challenges and learning from the programme has helped us refine our screening protocol to optimise migrant TB screening in Manchester in the future.


Latent Tuberculosis , Tuberculosis , Child , Adult , Humans , Latent Tuberculosis/diagnosis , Latent Tuberculosis/epidemiology , Afghanistan , Feasibility Studies , Tuberculosis/diagnosis , Interferon-gamma Release Tests/methods , Mass Screening
3.
Arch Dis Child ; 106(12): 1226-1228, 2021 12.
Article En | MEDLINE | ID: mdl-34158279

OBJECTIVE: To assess the impact of a virtual multidisciplinary team (MDT) review panel in reducing travel for children with a rare disease (tuberculosis (TB)) without compromising clinical outcomes. DESIGN: Retrospective review of patients discussed in a virtual MDT panel. Independent pre-intervention and post-intervention data from Public Health England. SETTING: Paediatric departments across North West England. PATIENTS: Children aged <16 years with suspected TB infection/disease. INTERVENTION: Weekly, virtual MDT discussion between district paediatricians and a tertiary TB team. MAIN OUTCOME MEASURE: Care closer to home, time from presentation to treatment. RESULTS: 45% (37 of 82) children received care closer to home. Median time from presentation to treatment reduced by 28% (from 18 to 13 days). 21% more children were diagnosed before developing symptoms (76% of children presented with symptoms pre-intervention, 55% post-intervention). 5 children incorrectly labelled with latent TB infection were treated for TB disease. CONCLUSIONS: A clinical network supported by virtual MDT reviews can improve treatment for children with rare diseases while providing care close to home.


Delivery of Health Care , Health Services Accessibility , Telemedicine , Tuberculosis , Child , Child, Preschool , England , Female , Humans , Infant , Infant, Newborn , Male , Pediatricians , Retrospective Studies , Tuberculosis/diagnosis , Tuberculosis/drug therapy
...